MENU
Pipeline
-
CAR-T Cell TherapyThe CAR-T cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a tumor-specific antigen, then integrates the fragment into the transmembrane chain segment consisting of a series of molecules involved in T cell activation such as CD28, 4-1BB and CD3-ζ, forming a recombinant plasmid CAR. The CAR will be transduced into the T cells of a patient and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-T cells will be generated to attack and eventually ablate the tumor.
-
CAR-NK Cell TherapyChimeric antigen receptor NK (CAR-NK) cell therapy is a gene engineering technology. It first transforms a fragment of scFv, an antibody capable of recognizing a specific tumor antigen and then integrates the fragment into the transmembrane chain segment composed of different combinations of molecules such as CD3-ζ, CD137, NKG2D and DAP10, forming a forming a recombinant plasmid CAR. The CAR will be transduced into the NK cells (from patients or healthy donors) and cause them to express CAR. After the “re-coding”, a large amount of tumor-specific CAR-NK cells will be generated to attack and eventually ablate the tumor.
-
More ProductsMore product columns are under construction, and treatment research will be carried out one by one in the future to benefit patients.
About Hrain
HRAIN Biotechnology is an innovative biopharmaceutical company dedicated to the R&D and manufacturing of breakthrough immunocellular therapies, with a primary focus on malignant hematological diseases and solid tumors, and expanding into therapeutic areas such as autoimmune diseases. Spearheaded by its proprietary CAR-T pipeline, the company has concurrently advanced cutting-edge technologies such as CAR-NK and UCAR-T, establishing a product pipeline spanning early-stage R&D, clinical trials, and commercialization. It currently holds 4 Class 1 innovative biological product IND approvals. Its CD19 CAR-T product HICARA® for relapsed or refractory non-Hodgkin lymphoma was approved for market launch in July 2025.
ALL
News
ALL
Manufacturing
Located in Shanghai Jinshan Industrial Park, the manufacturing base owns GMP certificated virus and CAR-T cell production workshops, process R&D technology center, product quality control technology center.
ALL
